NovoCure Ltd. (NVCR)
11.55
-0.06
(-0.52%)
USD |
NASDAQ |
Mar 26, 13:34
NovoCure Cash from Investing (Quarterly) : 336.33M for Dec. 31, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| LivaNova Plc | -30.26M |
| AtriCure, Inc. | -2.602M |
| Abbott Laboratories | -913.00M |
| Accuray, Inc. | -5.596M |
| Plus Therapeutics, Inc. | -1.077M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -18.00M |
| Cash from Financing (Quarterly) | -559.49M |
| Free Cash Flow | -75.68M |
| Free Cash Flow Per Share (Quarterly) | -0.204 |
| Free Cash Flow to Equity (Quarterly) | 526.69M |
| Free Cash Flow to Firm (Quarterly) | -22.56M |
| Free Cash Flow Yield | -5.88% |